NovoCodex Collaborates with Ambrx to Develop and Commercialize its ARX305 in China

 NovoCodex Collaborates with Ambrx to Develop and Commercialize its ARX305 in China

NovoCodex Collaborates with Ambrx to Develop and Commercialize its ARX305 in China

Shots:

  • Ambrx to receive up front, development milestones and royalties on sales of ARX305 in China and retain rights to develop & commercialize ARX305 outside China. NovoCodex to get right to develop & commercialize ARX305 in China, will fund global activities to the end of P-I and is eligible to share ARX305 sales outside China
  • Earlier, the companies collaborated to develop & commercialize ARX788, which is currently in P-I study for HER2 positive breast and gastric cancers
  • ARX305 is an anti-CD70 ADC, expected to deliver direct killing to CD70-overexpressing tumor and improvement of the immune suppression in the tumor microenvironment with its anticipated onset of P-I study in H1’21  

Click here to­ read full press release/ article | Ref: PRNewswire | Image: Xconomy

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post